Want to see JAZZ full AI Analyst Report?
JAZZ Stock Chart & Stats
$203.42
-$1.17(-0.95%)
At close: 4:00 PM EST
$203.42
-$1.17(-0.95%)
Day’s Range― - ―
52-Week Range$105.00 - $243.32
Previous CloseN/A
Volume75.28K
Average Volume (3M)933.57K
Market Cap
$15.29B
Enterprise Value$17.83B
Total Cash (Recent Filing)$2.87B
Total Debt (Recent Filing)$5.42B
Price to Earnings (P/E)593.8
Beta0.68
Next Earnings
Aug 05, 2026EPS Estimate
6.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding62,817,627
10 Day Avg. Volume920,738
30 Day Avg. Volume933,571
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.40
Price to Sales (P/S)2.43
P/FCF Ratio9.05
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda32.76
Forecast
1Y Price Target
$262.93Price Target Upside29.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)25.37
Revenue Forecast (FY)$4.52B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent, large operating and free cash flow provides durable financial flexibility for R&D, commercialization, and debt servicing. Over a 2–6 month horizon this supports continued pipeline funding, commercialization of new launches, and optionality for M&A or buybacks despite volatile reported earnings.
Oncology Momentum & New LaunchesRapid oncology growth and early uptake of Midevo and ZYHERA diversify revenue away from concentration in sleep drugs. Sustainable oncology expansion reduces single-product risk, supports revenue resilience, and creates a multi-year commercial runway if trial and regulatory milestones continue to succeed.
High Gross MarginsVery high gross margins reflect pricing power and low cost-of-goods for specialty therapies, converting sales into substantial cash. This margin structure underpins long-term free cash flow generation and buffers R&D and commercial spend even when net income is episodically weak.
Bears Say
Elevated Absolute DebtDespite improved leverage metrics, a ~$5.4B absolute debt load constrains strategic flexibility and increases sensitivity to earnings volatility. Over the medium term this limits free capital for acquisitions or aggressive share returns and raises refinancing and interest-rate exposure risk.
Earnings VolatilityWide swings in net income and a very low TTM net margin (~0.7%) impair predictability of retained earnings and cash available after investment. For capital allocation and credit metrics, this volatility increases risk of covenant pressure and complicates long-term planning despite strong top-line and gross margins.
Structural Sleep‑Market CompetitionAnticipated generic oxybate volume and new wake‑promoter entrants threaten durable revenue and margin for the sleep franchise. Over months this can permanently reduce pricing power, increase marketing and access costs, and force greater reliance on oncology and new launches to sustain growth.
Jazz Pharmaceuticals News
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $105.00 and its highest was $243.32 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $15.29B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Aug 05, 2026 which is in 33 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on May 05, 2026. The company reported $6.34 earnings per share for the quarter, beating the consensus estimate of $4.641 by $1.699.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 6.16.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 62,817,627 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $6.34 in its last earnings report, beating expectations of $4.641. Following the earnings report the stock price went up 7.684%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$262.93 (29.25% Upside)
$262.93 (29.25% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 150.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 15.8%
Last 30 Days ▲ 15.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.49%
12-Months-Change
Fundamentals
Return on Equity
0.71%
Trailing 12-Months
Asset Growth
2.82%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ Company Deck
JAZZ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and substantial pipeline/regulatory progress that drove record Q1 revenue, robust product-level growth (notably oncology, Xywav and Epidiolex), solid cash generation and clear near-term catalysts (zanidatumab PDUFA, multiple interim readouts). Headline growth was partially boosted by an extra shipping week and FX effects, and management highlighted expected competitive dynamics in sleep and areas of margin and policy uncertainty. Overall, the positives (record revenue, high growth rates, cash strength, promising pivotal data and imminent regulatory milestones) outweigh the outlined risks and uncertainties.View all JAZZ earnings summariesJAZZ Stock 12 Month Forecast
Average Price Target
$262.93
▲(29.25% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Bio-Techne
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
3.54% Insiders
30.45% Mutual Funds
0.05% Other Institutional Investors
41.65% Public Companies and
Individual Investors